Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Greenwich LifeSciences (GLSI) Operating Expenses (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Operating Expenses readings, the most recent being $4.2 million for Q3 2025.

  • Quarterly Operating Expenses rose 52.97% to $4.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $19.6 million through Sep 2025, up 81.97% year-over-year, with the annual reading at $16.0 million for FY2024, 71.66% up from the prior year.
  • Operating Expenses hit $4.2 million in Q3 2025 for Greenwich LifeSciences, up from $4.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $8.1 million in Q4 2024 and bottomed at $600606.0 in Q1 2021.
  • Average Operating Expenses over 5 years is $2.6 million, with a median of $2.5 million recorded in 2023.
  • The largest annual shift saw Operating Expenses surged 258.05% in 2021 before it fell 2.03% in 2023.
  • Greenwich LifeSciences' Operating Expenses stood at $2.4 million in 2021, then grew by 21.77% to $2.9 million in 2022, then fell by 2.03% to $2.8 million in 2023, then skyrocketed by 185.05% to $8.1 million in 2024, then crashed by 48.36% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Operating Expenses are $4.2 million (Q3 2025), $4.0 million (Q2 2025), and $3.3 million (Q1 2025).